Symbols / IMVT $29.49 +4.28% Immunovant, Inc.
IMVT Chart
About
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Fundamentals
Scroll to Statements| Market Cap | 6.00B | Enterprise Value | 4.76B | Income | -464.20M | Sales | — | Book/sh | 4.85 | Cash/sh | 4.89 |
| Dividend Yield | — | Payout | 0.00% | Employees | 362 | IPO | — | P/E | — | Forward P/E | -11.41 |
| PEG | — | P/S | — | P/B | 6.08 | P/C | — | EV/EBITDA | -9.78 | EV/Sales | — |
| Quick Ratio | 15.04 | Current Ratio | 15.74 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -2.67 | EPS next Y | -2.58 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-28 | ROA | -41.33% | ROE | -69.35% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 203.53M | Shs Float | 77.46M | Short Float | 20.71% |
| Short Ratio | 14.23 | Short Interest | — | 52W High | 29.52 | 52W Low | 13.36 | Beta | 0.67 | Avg Volume | 1.38M |
| Volume | 1.85M | Target Price | $40.29 | Recom | Buy | Prev Close | $28.28 | Price | $29.49 | Change | 4.28% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-15 | main | Goldman Sachs | Neutral → Neutral | $32 |
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2026-02-09 | main | Guggenheim | Buy → Buy | $44 |
| 2026-01-08 | main | Truist Securities | Hold → Hold | $22 |
| 2026-01-06 | up | Wolfe Research | Peer Perform → Outperform | $50 |
| 2025-12-15 | main | Goldman Sachs | Neutral → Neutral | $28 |
| 2025-10-14 | init | Truist Securities | — → Hold | $16 |
| 2025-09-30 | main | JP Morgan | Overweight → Overweight | $33 |
| 2025-09-04 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-08-12 | main | JP Morgan | Overweight → Overweight | $37 |
| 2025-08-12 | main | B of A Securities | Buy → Buy | $30 |
| 2025-07-28 | main | UBS | Neutral → Neutral | $18 |
| 2025-04-22 | down | UBS | Buy → Neutral | $17 |
| 2025-03-20 | reit | Guggenheim | Buy → Buy | — |
| 2025-03-20 | main | B of A Securities | Buy → Buy | $33 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $51 |
| 2025-03-10 | reit | Guggenheim | Buy → Buy | — |
| 2025-02-10 | main | Guggenheim | Buy → Buy | $44 |
| 2025-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $51 |
| 2025-02-07 | reit | HC Wainwright & Co. | Buy → Buy | $51 |
- Immunovant: Best-In-Class Ambitions, Still Unproven (NASDAQ:IMVT) - Seeking Alpha Mon, 20 Apr 2026 13
- IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - Yahoo Finance Mon, 06 Apr 2026 07
- Immunovant (IMVT) Innovation Pipeline | Immunovant posts 16.3% EPS beat on narrower loss - Rating Downgrade - Xã Thanh Hà Wed, 22 Apr 2026 21
- How Immunovant Inc. (IMVT) Affects Rotational Strategy Timing - Stock Traders Daily ue, 21 Apr 2026 20
- Van Tuyl, Immunovant’s chief legal officer, sells $128k in IMVT stock - Investing.com Fri, 10 Apr 2026 07
- Immunovant (IMVT) director granted options and RSUs in new equity awards - Stock Titan hu, 09 Apr 2026 07
- Immunovant (NASDAQ:IMVT) Reaches New 12-Month High - Should You Buy? - MarketBeat Fri, 17 Apr 2026 22
- IMMUNOVANT Earnings Preview: Recent $IMVT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative Wed, 29 Oct 2025 07
- Assessing Immunovant (IMVT) Valuation After Recent Share Price Weakness - Yahoo Finance Sat, 14 Mar 2026 07
- Immunovant (IMVT) awards RSUs and stock options to director Jake Bauer - Stock Titan hu, 09 Apr 2026 07
- A Look At Immunovant (IMVT) Valuation After Trial Progress Updates And Extended Cash Runway - Yahoo Finance Sat, 07 Feb 2026 08
- Immunovant (IMVT) grants director Frank Torti RSUs and stock options - Stock Titan hu, 09 Apr 2026 07
- Is Immunovant (IMVT) Overvalued? Taking Stock of Its Premium Price-to-Book Multiple - Yahoo Finance ue, 02 Dec 2025 08
- Immunovant (IMVT) CTO granted 96,851 options and 66,937 RSUs - Stock Titan hu, 09 Apr 2026 07
- Immunovant (IMVT) CEO awarded new stock options and RSUs in equity grant - Stock Titan hu, 09 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
438.15
+62.15%
|
270.21
+29.74%
|
208.28
+33.48%
|
156.03
|
| Research And Development |
|
360.92
+69.50%
|
212.93
+32.87%
|
160.26
+57.41%
|
101.81
|
| Selling General And Administration |
|
77.23
+34.84%
|
57.28
+19.29%
|
48.02
-11.44%
|
54.23
|
| General And Administrative Expense |
|
77.23
+34.84%
|
57.28
+19.29%
|
48.02
-11.44%
|
54.23
|
| Other Gand A |
|
77.23
+34.84%
|
57.28
+19.29%
|
48.02
-11.44%
|
54.23
|
| Total Expenses |
|
438.15
+62.15%
|
270.21
+29.74%
|
208.28
+33.48%
|
156.03
|
| Operating Income |
|
-438.15
-62.15%
|
-270.21
-29.74%
|
-208.28
-33.48%
|
-156.03
|
| EBITDA |
|
-437.77
-62.15%
|
-269.98
-29.75%
|
-208.08
-33.47%
|
-155.91
|
| Normalized EBITDA |
|
-437.77
-70.02%
|
-257.48
-29.98%
|
-198.08
-27.05%
|
-155.91
|
| Reconciled Depreciation |
|
0.38
+63.20%
|
0.23
+19.69%
|
0.19
+53.17%
|
0.13
|
| EBIT |
|
-438.15
-62.15%
|
-270.21
-29.74%
|
-208.28
-33.48%
|
-156.03
|
| Total Unusual Items |
|
0.00
+100.00%
|
-12.50
-25.00%
|
-10.00
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
0.00
+100.00%
|
-12.50
-25.00%
|
-10.00
|
0.00
|
| Special Income Charges |
|
0.00
+100.00%
|
-12.50
-25.00%
|
-10.00
|
0.00
|
| Other Special Charges |
|
—
|
12.50
+25.00%
|
10.00
|
—
|
| Restructuring And Mergern Acquisition |
|
0.00
-100.00%
|
12.50
+25.00%
|
10.00
|
0.00
|
| Net Income |
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
-34.60%
|
-156.73
|
| Pretax Income |
|
-412.95
-59.58%
|
-258.77
-22.67%
|
-210.95
-34.52%
|
-156.81
|
| Net Non Operating Interest Income Expense |
|
24.73
-0.87%
|
24.95
+229.22%
|
7.58
|
0.00
|
| Net Interest Income |
|
24.73
-0.87%
|
24.95
+229.22%
|
7.58
|
0.00
|
| Interest Income Non Operating |
|
24.73
-0.87%
|
24.95
+229.22%
|
7.58
|
0.00
|
| Interest Income |
|
24.73
-0.87%
|
24.95
+229.22%
|
7.58
|
0.00
|
| Other Income Expense |
|
0.47
+103.49%
|
-13.51
-31.75%
|
-10.25
-1212.80%
|
-0.78
|
| Other Non Operating Income Expenses |
|
0.47
+146.73%
|
-1.01
-298.42%
|
-0.25
+67.61%
|
-0.78
|
| Tax Provision |
|
0.89
+57.14%
|
0.57
+6200.00%
|
0.01
+110.71%
|
-0.08
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
+100.00%
|
-2.62
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
-34.60%
|
-156.73
|
| Net Income From Continuing Operation Net Minority Interest |
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
-34.60%
|
-156.73
|
| Net Income From Continuing And Discontinued Operation |
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
-34.60%
|
-156.73
|
| Net Income Continuous Operations |
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
-34.60%
|
-156.73
|
| Normalized Income |
|
-413.84
-65.89%
|
-249.46
-24.13%
|
-200.96
-28.22%
|
-156.73
|
| Net Income Common Stockholders |
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
-34.60%
|
-156.73
|
| Diluted EPS |
|
-2.73
-45.21%
|
-1.88
-9.94%
|
-1.71
-19.58%
|
-1.43
|
| Basic EPS |
|
-2.73
-45.21%
|
-1.88
-9.94%
|
-1.71
-19.58%
|
-1.43
|
| Basic Average Shares |
|
151.57
+9.76%
|
138.10
+12.21%
|
123.08
+12.21%
|
109.68
|
| Diluted Average Shares |
|
151.57
+9.76%
|
138.10
+12.21%
|
123.08
+12.21%
|
109.68
|
| Diluted NI Availto Com Stockholders |
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
-34.60%
|
-156.73
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets |
|
776.22
+16.49%
|
666.37
+64.19%
|
405.84
-21.28%
|
515.56
|
| Current Assets |
|
767.66
+15.30%
|
665.77
+64.66%
|
404.33
-21.17%
|
512.93
|
| Cash Cash Equivalents And Short Term Investments |
|
713.97
+12.37%
|
635.37
+68.74%
|
376.53
-23.75%
|
493.82
|
| Cash And Cash Equivalents |
|
713.97
+12.37%
|
635.37
+68.74%
|
376.53
-23.75%
|
493.82
|
| Cash Financial |
|
—
|
—
|
—
|
493.82
|
| Receivables |
|
2.51
-54.37%
|
5.50
+521.81%
|
0.89
-93.12%
|
12.86
|
| Accounts Receivable |
|
2.08
-60.95%
|
5.34
+662.43%
|
0.70
-94.28%
|
12.23
|
| Taxes Receivable |
|
0.43
+157.23%
|
0.17
-10.27%
|
0.18
-70.73%
|
0.63
|
| Prepaid Assets |
|
—
|
—
|
—
|
6.25
|
| Other Current Assets |
|
51.18
+105.53%
|
24.90
-7.48%
|
26.92
+330.45%
|
6.25
|
| Total Non Current Assets |
|
8.56
+1338.66%
|
0.59
-60.47%
|
1.50
-42.84%
|
2.63
|
| Net PPE |
|
0.94
+58.32%
|
0.59
-60.47%
|
1.50
-42.84%
|
2.63
|
| Gross PPE |
|
0.94
+58.32%
|
0.59
-60.47%
|
1.50
-42.84%
|
2.63
|
| Other Properties |
|
0.94
+58.32%
|
0.59
-60.47%
|
1.50
-42.84%
|
2.63
|
| Other Non Current Assets |
|
7.62
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
68.78
+41.49%
|
48.61
+12.14%
|
43.34
-5.24%
|
45.74
|
| Current Liabilities |
|
68.78
+41.49%
|
48.61
+12.27%
|
43.30
-2.75%
|
44.52
|
| Payables And Accrued Expenses |
|
53.06
+57.32%
|
33.73
-2.51%
|
34.59
-11.11%
|
38.92
|
| Payables |
|
17.93
+150.06%
|
7.17
+321.02%
|
1.70
-90.94%
|
18.80
|
| Accounts Payable |
|
17.66
+146.76%
|
7.16
+428.82%
|
1.35
-92.74%
|
18.63
|
| Current Accrued Expenses |
|
35.13
+32.29%
|
26.56
-19.26%
|
32.89
+63.48%
|
20.12
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
15.62
+5.93%
|
14.74
+95.80%
|
7.53
+68.99%
|
4.46
|
| Current Debt And Capital Lease Obligation |
|
0.10
-28.99%
|
0.14
-88.24%
|
1.17
+2.45%
|
1.15
|
| Current Capital Lease Obligation |
|
0.10
-28.99%
|
0.14
-88.24%
|
1.17
+2.45%
|
1.15
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
-100.00%
|
0.05
-96.14%
|
1.22
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.05
-96.14%
|
1.22
|
| Long Term Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.05
-96.14%
|
1.22
|
| Stockholders Equity |
|
707.45
+14.52%
|
617.76
+70.42%
|
362.49
-22.84%
|
469.82
|
| Common Stock Equity |
|
707.45
+14.52%
|
617.76
+70.42%
|
362.49
-22.84%
|
469.82
|
| Capital Stock |
|
0.02
+14.29%
|
0.01
+7.69%
|
0.01
+8.33%
|
0.01
|
| Common Stock |
|
0.02
+14.29%
|
0.01
+7.69%
|
0.01
+8.33%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
170.11
+16.85%
|
145.58
+11.70%
|
130.33
+11.89%
|
116.48
|
| Ordinary Shares Number |
|
170.11
+16.85%
|
145.58
+11.70%
|
130.33
+11.89%
|
116.48
|
| Additional Paid In Capital |
|
1,945.49
+34.96%
|
1,441.52
+55.34%
|
927.98
+12.51%
|
824.80
|
| Retained Earnings |
|
-1,239.52
-50.12%
|
-825.68
-45.79%
|
-566.35
-59.36%
|
-355.39
|
| Gains Losses Not Affecting Retained Earnings |
|
1.46
-23.53%
|
1.91
+123.94%
|
0.85
+110.89%
|
0.40
|
| Other Equity Adjustments |
|
1.46
-23.53%
|
1.91
+123.94%
|
0.85
+110.89%
|
0.40
|
| Total Equity Gross Minority Interest |
|
707.45
+14.52%
|
617.76
+70.42%
|
362.49
-22.84%
|
469.82
|
| Total Capitalization |
|
707.45
+14.52%
|
617.76
+70.42%
|
362.49
-22.84%
|
469.82
|
| Working Capital |
|
698.89
+13.24%
|
617.16
+70.94%
|
361.04
-22.92%
|
468.41
|
| Invested Capital |
|
707.45
+14.52%
|
617.76
+70.42%
|
362.49
-22.84%
|
469.82
|
| Total Debt |
|
0.10
-28.99%
|
0.14
-88.69%
|
1.22
-48.39%
|
2.36
|
| Capital Lease Obligations |
|
0.10
-28.99%
|
0.14
-88.69%
|
1.22
-48.39%
|
2.36
|
| Net Tangible Assets |
|
707.45
+14.52%
|
617.76
+70.42%
|
362.49
-22.84%
|
469.82
|
| Tangible Book Value |
|
707.45
+14.52%
|
617.76
+70.42%
|
362.49
-22.84%
|
469.82
|
| Dueto Related Parties Current |
|
0.27
+1720.00%
|
0.01
-95.71%
|
0.35
+104.68%
|
0.17
|
| Preferred Shares Number |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-375.87
-75.46%
|
-214.23
-13.83%
|
-188.19
-77.35%
|
-106.11
|
| Cash Flow From Continuing Operating Activities |
|
-375.87
-75.46%
|
-214.23
-13.83%
|
-188.19
-77.35%
|
-106.11
|
| Net Income From Continuing Operations |
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
-34.60%
|
-156.73
|
| Depreciation Amortization Depletion |
|
0.38
+63.20%
|
0.23
+19.69%
|
0.19
+53.17%
|
0.13
|
| Depreciation |
|
0.38
+63.20%
|
0.23
+19.69%
|
0.19
+53.17%
|
0.13
|
| Depreciation And Amortization |
|
0.38
+63.20%
|
0.23
+19.69%
|
0.19
+53.17%
|
0.13
|
| Other Non Cash Items |
|
0.13
-88.23%
|
1.13
-0.09%
|
1.13
+2.26%
|
1.11
|
| Stock Based Compensation |
|
49.49
+20.36%
|
41.12
+27.31%
|
32.30
-5.69%
|
34.24
|
| Change In Working Capital |
|
-12.03
-557.10%
|
2.63
+124.25%
|
-10.85
-171.67%
|
15.14
|
| Change In Receivables |
|
2.97
+165.18%
|
-4.56
-137.28%
|
12.22
+204.33%
|
-11.72
|
| Changes In Account Receivables |
|
3.23
+170.61%
|
-4.58
-138.91%
|
11.76
+201.13%
|
-11.63
|
| Change In Prepaid Assets |
|
-26.99
-1832.35%
|
1.56
+107.59%
|
-20.53
-1060.83%
|
2.14
|
| Change In Payables And Accrued Expense |
|
19.86
+191.92%
|
6.80
+586.00%
|
-1.40
-105.40%
|
25.90
|
| Change In Accrued Expense |
|
8.92
+561.45%
|
1.35
-91.33%
|
15.57
+64.36%
|
9.47
|
| Change In Payable |
|
10.94
+100.53%
|
5.46
+132.15%
|
-16.97
-203.27%
|
16.43
|
| Change In Account Payable |
|
10.68
+84.72%
|
5.78
+133.78%
|
-17.12
-205.35%
|
16.25
|
| Change In Other Current Assets |
|
-7.74
|
0.00
|
0.00
|
—
|
| Change In Other Current Liabilities |
|
-0.14
+88.23%
|
-1.17
-2.36%
|
-1.15
+2.88%
|
-1.18
|
| Investing Cash Flow |
|
-0.76
-110.83%
|
-0.36
-82.74%
|
-0.20
+22.44%
|
-0.25
|
| Cash Flow From Continuing Investing Activities |
|
-0.76
-110.83%
|
-0.36
-82.74%
|
-0.20
+22.44%
|
-0.25
|
| Net PPE Purchase And Sale |
|
-0.76
-110.83%
|
-0.36
-82.74%
|
-0.20
+22.44%
|
-0.25
|
| Purchase Of PPE |
|
-0.76
-110.83%
|
-0.36
-82.74%
|
-0.20
+22.44%
|
-0.25
|
| Capital Expenditure |
|
-0.76
-110.83%
|
-0.36
-82.74%
|
-0.20
+22.44%
|
-0.25
|
| Financing Cash Flow |
|
454.49
-3.80%
|
472.43
+566.47%
|
70.89
-64.58%
|
200.13
|
| Cash Flow From Continuing Financing Activities |
|
454.49
-3.80%
|
472.43
+566.47%
|
70.89
-64.58%
|
200.13
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
450.00
-4.81%
|
472.75
+570.56%
|
70.50
|
0.00
|
| Proceeds From Stock Option Exercised |
|
4.81
-15.51%
|
5.69
+766.67%
|
0.66
|
0.00
|
| Net Other Financing Charges |
|
-0.32
+94.69%
|
-6.01
-2110.29%
|
-0.27
-100.14%
|
200.13
|
| Changes In Cash |
|
77.86
-69.80%
|
257.84
+319.43%
|
-117.50
-225.32%
|
93.76
|
| Effect Of Exchange Rate Changes |
|
0.75
-24.77%
|
0.99
+351.36%
|
0.22
+339.13%
|
-0.09
|
| Beginning Cash Position |
|
635.37
+68.74%
|
376.53
-23.75%
|
493.82
+23.41%
|
400.15
|
| End Cash Position |
|
713.97
+12.37%
|
635.37
+68.74%
|
376.53
-23.75%
|
493.82
|
| Free Cash Flow |
|
-376.63
-75.52%
|
-214.59
-13.91%
|
-188.39
-77.11%
|
-106.37
|
| Income Tax Paid Supplemental Data |
|
1.20
+136.15%
|
0.51
|
0.00
|
0.00
|
| Common Stock Issuance |
|
450.00
-4.81%
|
472.75
+570.56%
|
70.50
|
0.00
|
| Issuance Of Capital Stock |
|
450.00
-4.81%
|
472.75
+570.56%
|
70.50
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-10 View
- 42026-04-10 View
- 42026-04-10 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-03 View
- 42026-03-20 View
- 42026-02-27 View
- 10-Q2026-02-06 View
- 8-K2026-02-06 View
- 42026-01-23 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|